Lupin today signed an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharma (Sunovion) for a purchase price of $75 million. The company expects the transaction to be accretive to earnings in the first year, as per a statement from Lupin.
The statement also said that the acquisition of these two brands expands Lupin’s portfolio of inhalation products in the US and strengthens the company’s presence in the respiratory therapy area while continuing to provide patients access to these important medicines.
While Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema, Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA) indicated for the treatment or prevention of bronchospasm in adults, adolescents and children four years of age or older with reversible obstructive airway disease, concluded the statement.